Clinical Research Directory

Inclusion Criteria: * Male or female, 21 to 75 years * Has diagnosis of Parkinson's disease (PD) per UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria; * Has modified Hoehn and Yahr Stage I to III in the 'OFF' state; * Presence of a pathogenic or likely pathogenic GBA1 mutation confirmed; * Must be generally ambulatory, not dependent on wheelchair; * Has a body weight of ≥40 kg (88 lb) to ≤110 kg (242 lb) and a body mass index (BMI) of 18 to 34 kg/m2; * Participant has a reliable study partner/informant (eg, family member, friend) willing and able to participate in the trial as a source of information on the participant's health status and cognitive and functional abilities; * Is living in the community (ie not in a nursing home) Exclusion Criteria: * Presence of a bi-allelic GBA1 mutation, or presence of LRRK2 2019S or other LRRK2 mutation; * Diagnosis of significant central nervous system (CNS) disease other than PD that may be a cause for the participant's PD symptoms or may confound study objectives; * Montreal Cognitive Assessment (MoCA) score of ≤22; * History of deep brain stimulator placement, focused ultrasound therapy, or other intercranial surgery for PD; * Hypersensitivity or contraindications to corticosteroid; * Prior gene or cell therapy; * Positive test result for anti-capsid total antibodies (tAb); * Unable to undergo lumbar puncture; * Diagnosis of Gaucher disease; * Clinically significant abnormalities in safety lab tests, vital signs; * Other illnesses or medications that may affect the interpretation of the study results.